---
title: Virology
order: 2
category: Microbiology
status: complete
last_updated: '2025-01-09'
---

# Virology

## Overview

Virology is the study of viruses, obligate intracellular parasites that require host cellular machinery for replication. Viruses are among the smallest infectious agents (20-300 nm) and consist of genetic material (DNA or RNA) surrounded by a protein coat (capsid), with or without a lipid envelope. Viral infections range from self-limited illnesses to chronic diseases and life-threatening conditions, representing a major cause of morbidity and mortality worldwide.

Unlike bacteria, viruses lack metabolic machinery and ribosomes, making them completely dependent on host cells for reproduction. This unique biology presents challenges for antiviral therapy, as targeting viral replication often affects host cell functions. Understanding viral structure, replication cycles, pathogenesis, and host immune responses is essential for clinical diagnosis, treatment, and prevention of viral diseases.

### Key Characteristics

**Viral Properties**:
- Obligate intracellular parasites
- No independent metabolism or protein synthesis
- Genome: DNA or RNA (never both)
- Size: 20-300 nanometers (smaller than bacteria)
- Replication: Assembly of pre-formed components (not binary fission)

**Viral Structure**:
- **Nucleic acid**: Genetic material (DNA or RNA, single or double-stranded)
- **Capsid**: Protein coat protecting genetic material
- **Envelope**: Lipid bilayer (some viruses) derived from host cell membranes
- **Virion**: Complete infectious viral particle

## Classification and Structure

### Classification by Nucleic Acid

**DNA Viruses**:
- Generally replicate in nucleus (except poxvirus)
- Use host DNA polymerase (except poxvirus and hepatitis B)
- More stable than RNA viruses

**RNA Viruses**:
- Generally replicate in cytoplasm (except influenza and retroviruses)
- Use viral RNA polymerase (error-prone, no proofreading)
- Higher mutation rates than DNA viruses
- **Positive-sense (+)**: RNA can directly serve as mRNA
- **Negative-sense (-)**: RNA must be transcribed to mRNA first

### Classification by Envelope

**Enveloped Viruses**:
- Lipid bilayer with viral glycoproteins
- Acquired by budding through host membranes
- Sensitive to heat, detergents, drying (less stable)
- Examples: Influenza, HIV, HSV, VZV, measles

**Non-enveloped (Naked) Viruses**:
- Protein capsid only
- Resistant to heat, detergents, drying (more stable)
- Released by cell lysis
- Examples: Adenovirus, parvovirus, poliovirus, norovirus

### Baltimore Classification

**Class I - dsDNA Viruses**:
- Herpesviruses, adenovirus, poxvirus, papillomavirus

**Class II - ssDNA Viruses**:
- Parvovirus B19

**Class III - dsRNA Viruses**:
- Rotavirus, reovirus

**Class IV - (+) ssRNA Viruses**:
- Poliovirus, hepatitis A, hepatitis C, SARS-CoV-2, flaviviruses

**Class V - (-) ssRNA Viruses**:
- Influenza, measles, mumps, rabies, RSV, Ebola

**Class VI - ssRNA-RT (Retroviruses)**:
- HIV, HTLV

**Class VII - dsDNA-RT**:
- Hepatitis B virus

## Pathophysiology

### Viral Replication Cycle

**Steps in Viral Replication**:

1. **Attachment (Adsorption)**:
   - Viral surface proteins bind specific host cell receptors
   - Examples: HIV gp120 to CD4, rhinovirus to ICAM-1, rabies to nicotinic acetylcholine receptor

2. **Penetration and Uncoating**:
   - **Enveloped viruses**: Membrane fusion or receptor-mediated endocytosis
   - **Non-enveloped viruses**: Direct penetration or endocytosis
   - Uncoating releases viral genome into cytoplasm or nucleus

3. **Biosynthesis**:
   - **DNA viruses**: DNA → mRNA → proteins (nucleus)
   - **RNA viruses**: RNA → mRNA → proteins (cytoplasm)
   - **Retroviruses**: RNA → DNA → mRNA → proteins (reverse transcription)

4. **Assembly**:
   - Viral components packaged into new virions
   - Occurs in nucleus or cytoplasm depending on virus

5. **Release**:
   - **Enveloped viruses**: Budding (cell may survive)
   - **Non-enveloped viruses**: Lysis (cell death)

### Viral Pathogenesis

**Viral Entry Routes**:
- Respiratory tract (influenza, rhinovirus, adenovirus)
- Gastrointestinal tract (rotavirus, norovirus, poliovirus)
- Skin/mucosa (HSV, HPV, rabies)
- Sexual transmission (HIV, HSV-2, HPV)
- Blood-borne (HBV, HCV, HIV)
- Vertical (congenital infections)

**Tissue Tropism**:
Determined by:
- Presence of specific cellular receptors
- Cellular machinery for replication
- Host immune defenses
- Environmental factors (pH, temperature)

**Viral Spread**:
- **Local**: Contiguous cell-to-cell spread
- **Viremia**: Bloodstream dissemination (primary and secondary)
- **Neural**: Retrograde axonal transport (rabies, HSV, VZV)

**Mechanisms of Viral Damage**:
- Direct cytopathic effects (cell lysis)
- Immunopathology (host immune response damage)
- Oncogenic transformation (HPV, EBV, HBV, HCV)
- Persistent/latent infections (herpesviruses, HIV)

### Immune Evasion Strategies

**Viral Mechanisms**:
- Antigenic variation (influenza, HIV)
- Inhibition of MHC class I presentation (CMV, EBV)
- Production of cytokine homologs (poxviruses)
- Latency in immune-privileged sites (HSV in ganglia)
- Rapid mutation (HIV, hepatitis C)
- Inhibition of interferon signaling
- Immune cell targeting (HIV infects CD4+ T cells)

## Clinical Presentation

### DNA Viruses

**Herpesviridae Family**:

**Herpes Simplex Virus Type 1 (HSV-1)**:
- **Diseases**: Oral herpes (gingivostomatitis), herpes labialis ("cold sores"), keratitis, encephalitis
- Latency in trigeminal ganglia
- Reactivation with stress, UV exposure, immunosuppression

**Herpes Simplex Virus Type 2 (HSV-2)**:
- **Diseases**: Genital herpes, neonatal herpes
- Latency in sacral ganglia
- Sexually transmitted

**Varicella-Zoster Virus (VZV)**:
- **Primary infection**: Varicella (chickenpox)
- **Reactivation**: Herpes zoster (shingles)
- Latency in dorsal root ganglia
- **Prevention**: Varicella vaccine, zoster vaccine

**Epstein-Barr Virus (EBV)**:
- **Diseases**: Infectious mononucleosis ("mono"), Burkitt lymphoma, nasopharyngeal carcinoma, post-transplant lymphoproliferative disorder
- Infects B lymphocytes
- Heterophile antibodies (monospot test)
- Atypical lymphocytes on blood smear

**Cytomegalovirus (CMV)**:
- **Diseases**: Mononucleosis-like syndrome (heterophile-negative), congenital infections (hearing loss, intellectual disability), retinitis in AIDS, pneumonitis in transplant patients
- Most common congenital infection
- "Owl's eye" inclusion bodies

**Human Herpesvirus 6 (HHV-6)**:
- **Disease**: Roseola infantum (exanthem subitum)
- High fever followed by rash as fever breaks

**Human Herpesvirus 8 (HHV-8)**:
- **Disease**: Kaposi sarcoma (in AIDS patients)

**Adenovirus**:
- Non-enveloped dsDNA virus
- **Diseases**: Pharyngitis, pneumonia, gastroenteritis, conjunctivitis ("pink eye"), hemorrhagic cystitis
- Serotypes 40/41 cause infantile gastroenteritis
- Common in military recruits

**Papillomaviridae**:

**Human Papillomavirus (HPV)**:
- Non-enveloped dsDNA virus
- **Diseases**:
  - Types 1, 2: Common warts
  - Types 6, 11: Genital warts (condyloma acuminata)
  - Types 16, 18: Cervical cancer, oropharyngeal cancer
- **Prevention**: HPV vaccine (Gardasil 9)
- E6 and E7 oncoproteins inactivate p53 and Rb

**Poxviridae**:

**Variola Virus**:
- **Disease**: Smallpox (eradicated 1980)
- Only DNA virus replicating in cytoplasm
- Contains its own DNA-dependent RNA polymerase

**Molluscum Contagiosum Virus**:
- **Disease**: Umbilicated papules
- Common in children and immunocompromised

**Hepadnaviridae**:

**Hepatitis B Virus (HBV)**:
- Partially dsDNA virus with reverse transcriptase
- **Disease**: Acute and chronic hepatitis, cirrhosis, hepatocellular carcinoma
- Surface antigen (HBsAg), core antigen (HBcAg), e antigen (HBeAg)
- **Transmission**: Blood, sexual, vertical
- **Prevention**: HBV vaccine

**Parvoviridae**:

**Parvovirus B19**:
- Smallest DNA virus (ssDNA)
- **Diseases**:
  - Fifth disease (erythema infectiosum) in children
  - Aplastic crisis in sickle cell disease
  - Hydrops fetalis in pregnancy
- "Slapped cheek" rash

### RNA Viruses

**Orthomyxoviridae**:

**Influenza Virus**:
- Segmented (-) ssRNA virus
- **Diseases**: Influenza (flu), secondary bacterial pneumonia
- Types A, B, C (A causes pandemics)
- Hemagglutinin (H) and neuraminidase (N) surface proteins
- **Antigenic drift**: Point mutations (seasonal epidemics)
- **Antigenic shift**: Reassortment (pandemics)
- **Treatment**: Oseltamivir (neuraminidase inhibitor)
- **Prevention**: Annual inactivated or live attenuated vaccine

**Paramyxoviridae**:

**Measles Virus (Rubeola)**:
- (-) ssRNA virus
- **Disease**: Measles
- 3 C's: Cough, coryza, conjunctivitis
- Koplik spots (pathognomonic)
- **Complications**: Pneumonia, encephalitis, SSPE (subacute sclerosing panencephalitis)
- **Prevention**: MMR vaccine

**Mumps Virus**:
- (-) ssRNA virus
- **Disease**: Parotitis, orchitis (sterility), aseptic meningitis, pancreatitis
- **Prevention**: MMR vaccine

**Respiratory Syncytial Virus (RSV)**:
- (-) ssRNA virus
- **Disease**: Bronchiolitis and pneumonia in infants
- Most common cause of lower respiratory infection in children
- Multinucleated giant cells
- **Prevention**: Palivizumab (monoclonal antibody for high-risk infants)

**Parainfluenza Virus**:
- (-) ssRNA virus
- **Disease**: Croup (laryngotracheobronchitis)
- "Steeple sign" on chest X-ray

**Rhabdoviridae**:

**Rabies Virus**:
- (-) ssRNA, bullet-shaped virus
- **Disease**: Rabies (fatal encephalitis)
- Transmitted via animal bites (raccoons, bats, foxes, skunks)
- Retrograde axonal transport to CNS
- Hydrophobia, aerophobia
- Negri bodies (cytoplasmic inclusions in neurons)
- **Prevention**: Post-exposure prophylaxis (vaccine + immunoglobulin)

**Togaviridae**:

**Rubella Virus**:
- (+) ssRNA virus
- **Disease**: Rubella (German measles)
- Mild rash, lymphadenopathy
- **Congenital rubella syndrome**: Cataracts, deafness, heart defects, intellectual disability
- **Prevention**: MMR vaccine

**Flaviviridae**:

**Hepatitis C Virus (HCV)**:
- (+) ssRNA virus
- **Disease**: Chronic hepatitis (85%), cirrhosis, hepatocellular carcinoma
- Most common cause of liver transplantation
- **Transmission**: Blood (IV drug use, transfusions pre-1992)
- **Treatment**: Direct-acting antivirals (DAAs) - cure >95%

**Dengue Virus**:
- (+) ssRNA virus, transmitted by Aedes mosquitoes
- **Diseases**: Dengue fever, dengue hemorrhagic fever
- Antibody-dependent enhancement with second infection

**Yellow Fever Virus**:
- (+) ssRNA virus, transmitted by Aedes mosquitoes
- **Disease**: Yellow fever (jaundice, hemorrhage)
- Councilman bodies (liver necrosis)
- Live attenuated vaccine available

**West Nile Virus**:
- (+) ssRNA virus, transmitted by Culex mosquitoes
- **Diseases**: Asymptomatic (80%), febrile illness, meningoencephalitis
- Birds are reservoir

**Zika Virus**:
- (+) ssRNA virus, transmitted by Aedes mosquitoes
- **Diseases**: Mild febrile illness, Guillain-Barré syndrome, congenital microcephaly

**Picornaviridae**:

**Poliovirus**:
- (+) ssRNA virus
- **Disease**: Poliomyelitis (asymmetric flaccid paralysis)
- Fecal-oral transmission
- Anterior horn cell destruction
- **Prevention**: Inactivated (Salk) or oral live attenuated (Sabin) vaccine
- Near eradication globally

**Coxsackievirus**:
- (+) ssRNA virus
- **Diseases**:
  - Coxsackie A: Hand-foot-mouth disease, herpangina
  - Coxsackie B: Myocarditis, pericarditis

**Echovirus**:
- (+) ssRNA virus
- **Diseases**: Aseptic meningitis, rash

**Hepatitis A Virus (HAV)**:
- (+) ssRNA virus
- **Disease**: Acute hepatitis (self-limited, no chronic form)
- Fecal-oral transmission
- **Prevention**: Inactivated vaccine

**Rhinovirus**:
- (+) ssRNA virus (>100 serotypes)
- **Disease**: Common cold
- Transmission via respiratory droplets and fomites
- Replicates at 33°C (nasal passages)

**Caliciviridae**:

**Norovirus**:
- (+) ssRNA virus
- **Disease**: Epidemic gastroenteritis (cruise ships, schools)
- Projectile vomiting, watery diarrhea
- Very contagious, small inoculum needed

**Reoviridae**:

**Rotavirus**:
- dsRNA virus (segmented)
- **Disease**: Infantile diarrhea (most common cause worldwide)
- Fecal-oral transmission
- **Prevention**: Live oral vaccine (RotaTeq, Rotarix)

**Coronaviridae**:

**SARS-CoV-2**:
- (+) ssRNA virus, enveloped
- **Disease**: COVID-19
- Respiratory symptoms, loss of smell/taste, multisystem involvement
- Spike protein binds ACE2 receptor
- **Treatment**: Paxlovid, remdesivir, monoclonal antibodies
- **Prevention**: mRNA vaccines (Pfizer, Moderna)

**SARS-CoV** and **MERS-CoV**:
- (+) ssRNA viruses causing severe respiratory syndromes

**Filoviridae**:

**Ebola Virus**:
- (-) ssRNA virus, filamentous
- **Disease**: Ebola hemorrhagic fever
- High mortality rate
- Transmitted via body fluids
- Outbreaks in Africa

### Retroviruses

**Human Immunodeficiency Virus (HIV)**:
- (+) ssRNA retrovirus (2 copies of genome)
- Reverse transcriptase converts RNA to DNA
- Integrase incorporates viral DNA into host chromosome
- **Transmission**: Sexual, blood, vertical
- **Target**: CD4+ T cells (via gp120 binding CD4 and CCR5/CXCR4 co-receptors)

**HIV-1** (most common globally):

**Acute HIV Infection**:
- Mononucleosis-like illness
- High viral load, CD4 count drops then recovers

**Chronic HIV Infection**:
- Asymptomatic or persistent generalized lymphadenopathy
- Progressive CD4+ T cell decline

**AIDS** (CD4 < 200 cells/μL):
- Opportunistic infections (PCP, CMV, Cryptococcus, Toxoplasma, MAC)
- Malignancies (Kaposi sarcoma, NHL, cervical cancer)
- Wasting, dementia

**Diagnosis**:
- 4th generation Ag/Ab test (p24 antigen + antibodies)
- Confirmatory: Western blot or HIV-1/HIV-2 differentiation
- CD4 count and viral load monitoring

**Treatment**:
- Combination antiretroviral therapy (cART/HAART)
- **NRTIs**: Zidovudine, tenofovir, emtricitabine
- **NNRTIs**: Efavirenz, nevirapine
- **Protease inhibitors**: Atazanavir, darunavir, ritonavir
- **Integrase inhibitors**: Raltegravir, dolutegravir
- **Entry/fusion inhibitors**: Maraviroc, enfuvirtide

**Prevention**:
- Safe sex practices, harm reduction
- PrEP (pre-exposure prophylaxis): Truvada, Descovy
- PEP (post-exposure prophylaxis)
- Treatment as prevention (U=U: undetectable = untransmittable)

**Human T-cell Lymphotropic Virus (HTLV-1)**:
- Retrovirus
- **Diseases**: Adult T-cell leukemia/lymphoma, tropical spastic paraparesis
- Endemic in Japan, Caribbean, Africa

## Diagnosis

### Viral Detection Methods

**Direct Detection**:

1. **Viral Culture**:
   - Cell culture inoculation
   - Observation of cytopathic effects (CPE)
   - Slow (days to weeks), labor-intensive
   - Gold standard for some viruses

2. **Antigen Detection**:
   - ELISA, immunofluorescence
   - Rapid influenza, RSV, rotavirus tests
   - HBsAg, HIV p24 antigen

3. **Nucleic Acid Testing (NAAT)**:
   - **PCR**: Highly sensitive and specific
   - **Real-time PCR**: Quantitative viral load (HIV, HCV, CMV)
   - Rapid diagnosis (hours)
   - Most common method currently

4. **Electron Microscopy**:
   - Direct visualization of viral particles
   - Limited use, requires high viral load

**Indirect Detection (Serology)**:

1. **Antibody Detection**:
   - **IgM**: Acute infection
   - **IgG**: Past infection or immunity
   - ELISA, Western blot, immunofluorescence

2. **Interpretation**:
   - Seroconversion: Negative to positive (acute infection)
   - 4-fold rise in titer: Acute infection
   - Single high titer: Recent or past infection

**Viral Load Monitoring**:
- Quantitative PCR for HIV, HBV, HCV, CMV
- Guides treatment decisions
- Monitors treatment response

## Treatment

### Antiviral Mechanisms

**Inhibition of Viral Attachment/Entry**:
- **Maraviroc**: CCR5 antagonist (HIV)
- **Enfuvirtide**: Fusion inhibitor (HIV)
- Monoclonal antibodies (COVID-19, RSV)

**Inhibition of Viral Uncoating**:
- **Amantadine, rimantadine**: M2 ion channel blockers (influenza A) - resistance now common

**Inhibition of Nucleic Acid Synthesis**:

1. **Nucleoside/Nucleotide Analogs**:
   - **Acyclovir, valacyclovir**: HSV, VZV (requires viral thymidine kinase)
   - **Ganciclovir, valganciclovir**: CMV
   - **Cidofovir**: CMV, adenovirus
   - **Ribavirin**: RSV, HCV (with interferon)
   - **Tenofovir, emtricitabine**: HIV, HBV
   - **Zidovudine**: HIV (NRTI)

2. **Non-Nucleoside Analogs**:
   - **Efavirenz, nevirapine**: HIV (NNRTIs)

3. **Polymerase Inhibitors**:
   - **Sofosbuvir**: HCV NS5B polymerase inhibitor
   - **Remdesivir**: SARS-CoV-2 RNA polymerase inhibitor

**Inhibition of Viral Replication**:
- **Integrase inhibitors**: Raltegravir, dolutegravir (HIV)

**Inhibition of Viral Assembly/Release**:
- **Neuraminidase inhibitors**: Oseltamivir, zanamivir (influenza)
- **Protease inhibitors**: Atazanavir, darunavir, ritonavir (HIV); nirmatrelvir (COVID-19)

**Immune Modulation**:
- **Interferons**: IFN-α for HBV, HCV
- Enhance antiviral state, upregulate MHC

### Antiviral Resistance

**Mechanisms**:
- Mutations in viral polymerase (acyclovir resistance in HSV)
- Mutations in thymidine kinase (ganciclovir resistance in CMV)
- Protease mutations (HIV PI resistance)
- Reverse transcriptase mutations (HIV NRTI/NNRTI resistance)

**Prevention**:
- Combination therapy (HIV cART)
- Adherence to treatment regimens
- Monitoring viral load and resistance testing

### Specific Antiviral Agents

**Herpesvirus Infections**:
- Acyclovir, valacyclovir (HSV, VZV)
- Famciclovir (HSV, VZV)
- Ganciclovir, valganciclovir, foscarnet (CMV)
- Cidofovir (resistant CMV, adenovirus)

**Influenza**:
- Oseltamivir, zanamivir (neuraminidase inhibitors)
- Baloxavir (endonuclease inhibitor)

**HIV**:
- cART: Combination of 3+ drugs from different classes
- Typical regimen: 2 NRTIs + integrase inhibitor or NNRTI or PI

**Hepatitis B**:
- Nucleos(t)ide analogs: Tenofovir, entecavir
- Interferon-α (pegylated)

**Hepatitis C**:
- Direct-acting antivirals (DAAs):
  - NS3/4A protease inhibitors: Glecaprevir, grazoprevir
  - NS5A inhibitors: Ledipasvir, velpatasvir
  - NS5B polymerase inhibitors: Sofosbuvir
- Combination regimens achieve >95% cure

**COVID-19**:
- Nirmatrelvir/ritonavir (Paxlovid)
- Remdesivir
- Monoclonal antibodies (limited use due to resistance)

## Prevention

### Vaccination

**Live Attenuated Vaccines**:
- MMR (measles, mumps, rubella)
- Varicella (chickenpox)
- Zoster (shingles) - Zostavax
- Rotavirus (oral)
- Intranasal influenza
- Yellow fever
- **Contraindicated**: Pregnancy, immunocompromised

**Inactivated/Killed Vaccines**:
- Polio (Salk vaccine - IPV)
- Hepatitis A
- Rabies
- Influenza (intramuscular)

**Subunit/Component Vaccines**:
- Hepatitis B (recombinant HBsAg)
- HPV (virus-like particles)
- Influenza (recombinant HA)
- Zoster (Shingrix - recombinant subunit)

**mRNA Vaccines**:
- COVID-19 (Pfizer-BioNTech, Moderna)
- Encodes spike protein, induces immune response

### Infection Control

**Standard Precautions**:
- Hand hygiene
- PPE for blood/body fluid exposure
- Safe injection practices

**Transmission-Based Precautions**:
- **Airborne**: Measles, varicella, tuberculosis (N95 respirator)
- **Droplet**: Influenza, mumps, rubella (surgical mask)
- **Contact**: HSV, RSV, norovirus (gowns, gloves)

**Public Health Measures**:
- Surveillance and outbreak investigation
- Isolation and quarantine
- Contact tracing
- Vector control (mosquito-borne viruses)
- Safe water and sanitation

### Prophylaxis

**Post-Exposure Prophylaxis**:
- **Rabies**: Vaccine + immunoglobulin
- **HIV**: cART within 72 hours
- **Hepatitis B**: Vaccine + HBIG (if unvaccinated)
- **Varicella**: VZIG or acyclovir (immunocompromised)

**Pre-Exposure Prophylaxis**:
- **HIV**: Truvada or Descovy for high-risk individuals
- **Influenza**: Annual vaccination

**Passive Immunization**:
- Immunoglobulin products
- Monoclonal antibodies (palivizumab for RSV)

## Key Points

1. Viruses are obligate intracellular parasites requiring host cellular machinery
2. Classification by nucleic acid type, envelope, and replication strategy guides understanding
3. Viral tropism is determined by specific receptor-host cell interactions
4. Herpesviruses establish latency and can reactivate
5. Influenza undergoes antigenic drift (epidemics) and shift (pandemics)
6. HIV targets CD4+ T cells, causing progressive immunodeficiency
7. Hepatitis B and C can cause chronic infection, cirrhosis, and hepatocellular carcinoma
8. Antivirals target specific stages of viral replication
9. Vaccines are the most effective prevention strategy for many viral diseases
10. Combination antiviral therapy reduces resistance development (HIV, HCV)
11. Nucleic acid testing (PCR) is the most sensitive and specific diagnostic method
12. Understanding viral replication cycles informs therapeutic strategies

## References

1. Knipe DM, Howley PM. Fields Virology. 7th ed. Wolters Kluwer; 2021.
2. Richman DD, Whitley RJ, Hayden FG. Clinical Virology. 4th ed. ASM Press; 2016.
3. Murray PR, et al. Medical Microbiology. 9th ed. Elsevier; 2021.
4. Kasper DL, et al. Harrison's Principles of Internal Medicine. 21st ed. McGraw-Hill; 2022.
5. Centers for Disease Control and Prevention. Immunization Schedules. www.cdc.gov/vaccines. 2024.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. 2023.
7. AASLD-IDSA. Recommendations for Testing, Managing, and Treating Hepatitis C. www.hcvguidelines.org. 2023.
